Search

Displaying results 4411 - 4420 of 10000 in total
  1. Drug

    Malacidin B

    go.drugbank.com/drugs/DB14052
    Experimental

    Malacidin B, along with [DB14051], is a member of a class of chemicals made by bacteria found in soil that can kill Gram-positive bacteria [A33312].

  2. Drug

    Malacidin A

    go.drugbank.com/drugs/DB14051
    Experimental

    Malacidin A, along with [DB14052], is a member of a class of chemicals made by bacteria found in soil that can kill Gram-positive bacteria [A33312].

  3. Drug

    NCX 1022

    go.drugbank.com/drugs/DB05410
    Experimental

    NCX is an NO-releasing derivative of hydrocortisone.

  4. Drug

    Metaxalone

    go.drugbank.com/drugs/DB00660
    ApprovedInvestigational

    Metaxalone is a moderate to strong muscle relaxant used in the symptomatic treatment of musculoskeletal pain caused by strains, sprains, and other musculoskeletal conditions.

  5. Drug

    Bucillamine

    go.drugbank.com/drugs/DB12160
    Investigational

    Bucillamine has been used in trials studying the treatment and prevention of Gout and Rheumatoid Arthritis.

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    IMC-1C11

    go.drugbank.com/drugs/DB06101
    Experimental

    IMC-1C11 is an anti-angiogenesis agent.

  7. Drug

    Rabeximod

    go.drugbank.com/drugs/DB05772
    Investigational

    Rabeximod is an orally administered compound for treatment of moderate or severe active rheumatoid arthritis that is currently undergoing phase II clinical testing in eight European countries.

  8. Drug

    Tezosentan

    go.drugbank.com/drugs/DB06558
    Investigational

    Tezosentan is an intravenous endothelin receptor A/B antagonist. … Tezosentan was initially developed for vasodilation in patients with acute heart failure but studies have shown that it does not assist in the treatment of dyspnea or prevent cardiovascular events.

  9. Drug

    CCX915

    go.drugbank.com/drugs/DB05159
    Experimental

    CCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders.

  10. Drug

    Influenza B virus B/Austria/1359417/2021 live (attenuated) antigen

    go.drugbank.com/drugs/DB16902
    Approved

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals.